Autor:	J, van der Lelie
Jazyk:	Dutch; Flemish
Rok vydání:	2008
Předmět:	Treatment Outcome Neovascularization Pathologic Neoplasms Humans Anemia Antineoplastic Agents Thrombosis Erythropoietin Survival Analysis
Zdroj:	Nederlands tijdschrift voor geneeskunde. 152(16)
ISSN:	0028-2162
Popis:	Erythropoietin has been shown to shorten survival in cancer patients under certain circumstances. Possible mechanisms are an increase in thrombotic events, tumour progression, and induction of angiogenesis. The FDA advises its use in oncology only as a replacement for blood transfusions in patients receiving chemotherapy. In these patients, a rise in haemoglobin above 7.4 mmol/l should be avoided.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::1ead1c75a32c75a8e5e3f85a38dbf2e3 https://pubmed.ncbi.nlm.nih.gov/18561787 Zobrazit plný text záznamu